Trump Names Heidi Overton to Lead FDA
White House physician adviser faces Senate confirmation

President Trump has selected Dr. Heidi Overton, a physician and senior White House domestic policy adviser, to serve as commissioner of the U.S. Food and Drug Administration (FDA). The nomination would place Overton in charge of the federal agency responsible for regulating prescription drugs, vaccines, medical devices, tobacco products and much of the nation's food supply. She would succeed former Commissioner Dr. Marty Makary, who stepped down in May 2026, with Kyle Diamantas serving as acting commissioner in the interim.
Overton currently serves as deputy assistant to the president on the Domestic Policy Council and previously held leadership roles at the America First Policy Institute and as a White House Fellow during President Trump's first administration. Administration officials say she has worked closely with Health and Human Services Secretary Robert F. Kennedy Jr. on healthcare policy and public health initiatives.
If confirmed by the Senate, Overton would inherit an agency overseeing thousands of prescription drug reviews, food safety inspections, medical device approvals and vaccine regulation. Her nomination comes during a period of significant policy changes at the FDA and follows months of leadership turnover that left the agency under interim management. Her confirmation process is expected to draw scrutiny over the administration's healthcare priorities, including vaccine policy, prescription drug regulation and broader FDA oversight.
The nomination now heads to the Senate Committee on Health, Education, Labor and Pensions (HELP) before a full Senate confirmation vote. If confirmed, Overton will help shape federal regulatory policy affecting the pharmaceutical industry, biotechnology companies, food manufacturers and healthcare providers nationwide while leading one of the government's most influential public health agencies.